Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

12.90USD
3:53pm EDT
Change (% chg)

$0.20 (+1.57%)
Prev Close
$12.70
Open
$12.50
Day's High
$12.90
Day's Low
$12.25
Volume
37,325
Avg. Vol
52,074
52-wk High
$19.36
52-wk Low
$10.53

Latest Key Developments (Source: Significant Developments)

Otonomy loss per share $0.88
Thursday, 2 Mar 2017 04:18pm EST 

Otonomy Inc : Otonomy reports fourth quarter and full year 2016 financial results and provides corporate update .Qtrly loss per share $0.88.  Full Article

Otonomy initiates patient enrollment in phase 2 clinical trial of oto-104 as protectant against cisplatin-induced hearing loss
Thursday, 19 Jan 2017 07:30am EST 

Otonomy Inc : Otonomy initiates patient enrollment in phase 2 clinical trial of oto-104 as protectant against cisplatin-induced hearing loss . Otonomy initiates patient enrollment in phase 2 clinical trial of oto-104 as protectant against cisplatin-induced hearing loss .Otonomy Inc says is also conducting two phase 3 clinical trials for oto-104 in ménière's disease patients, with results expected in second half of 2017.  Full Article

Otonomy sees 2017 non-GAAP operating expenses between $85-$90 mln
Monday, 9 Jan 2017 07:30am EST 

Otonomy Inc : Otonomy provides corporate and product pipeline update .Expects non-GAAP operating expenses for 2017 in range of $85-$90 million.  Full Article

Otonomy reports third quarter 2016 financial results
Thursday, 3 Nov 2016 04:13pm EDT 

Otonomy Inc - : Company reaffirms its expectations that non-GAAP operating expenses for 2016 will total $100-$105 million . Says non-GAAP operating expenses for 2017 will not exceed levels for 2016 . Qtrly adjusted loss per share $2.48; qtrly loss per share $2.81 . Q3 earnings per share view $-0.95 -- Thomson Reuters I/B/E/S .Otonomy reports third quarter 2016 financial results and provides corporate update.  Full Article

Otonomy reiterates financial guidance, says non-gaap operating expenses for 2017 would not exceed 2016
Friday, 7 Oct 2016 08:00am EDT 

Otonomy Inc : Otonomy holds investor and analyst day and provides corporate update . Reiterated its financial guidance that non-gaap operating expenses for 2017 would not exceed 2016 . 2017 cash burn is expected to decline from 2016 due to flat operating expense level combined with expected increases in otiprio revenue . Otonomy reiterated its financial guidance that non-gaap operating expenses for 2016 would total $100-$105 million . Two identical phase 3 trials for oto-104 in ménière's disease are ongoing with results of both trials expected in second half of 2017 .Cash burn for 2017 is expected to decline from 2016 as a result of flat operating expense level.  Full Article

Otonomy Inc qtrly GAAP loss per share $0.87
Thursday, 4 Aug 2016 04:31pm EDT 

Otonomy Inc Qtrly Non : Company reaffirms its expectation that non-gaap operating expenses for 2016 will total $100-$105 million . Gaap loss per share $0.87 . Q2 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S .Otonomy inc qtrly gaap loss per share $0.98.  Full Article

Otonomy qtrly adjusted loss per share $0.81
Monday, 9 May 2016 04:16pm EDT 

Otonomy Inc Says Expects That Non : Otonomy inc says evelopment plan for 2016 has been expanded to include initiation and completion of a single phase 3 registration trial for otiprio . Gaap operating expenses for 2016 will total $100-$105 million . Qtrly adjusted loss per share $0.81 . Qtrly loss per share $0.91 . Q1 earnings per share view $-0.84, revenue view $517500.00 -- Thomson Reuters I/B/E/S .Otonomy reports first quarter 2016 financial results and provides corporate update.  Full Article

Otonomy Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:01pm EST 

Otonomy, Inc:commenced an underwritten public offering of approximately $100 million of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy.In addition, Otonomy expects to grant the underwriters a 30-day option to purchase up to an additional approximately $15 million of its common stock.The number of shares to be offered and the price for the proposed offering have not yet been determined.BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers of the proposed offering. Sanford C. Bernstein and SunTrust Robinson Humphrey are acting as co-managers.The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Otonomy announces FDA approval of OTIPRIO for treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
Friday, 11 Dec 2015 07:30am EST 

Otonomy Inc:Says that the U.S. Food and Drug Administration (FDA) has approved OTIPRIO for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.  Full Article

Otonomy Inc receives FDA clearance of investigational new drug application
Monday, 5 Oct 2015 07:30am EDT 

Otonomy Inc:Receives FDA clearance of investigational new drug application for tinnitus product candidate, oto-311.  Full Article

More From Around the Web

BRIEF-Otonomy loss per share $0.88

* Otonomy reports fourth quarter and full year 2016 financial results and provides corporate update